
Romi Ghose

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12166714/publications.pdf Version: 2024-02-01



POMI CHOSE

#	Article	IF	CITATIONS
1	Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation. Nuclear Receptor, 2004, 2, 4.	10.0	127
2	Induction of TAK (Cyclin T1/P-TEFb) in Purified Resting CD4 + T Lymphocytes by Combination of Cytokines. Journal of Virology, 2001, 75, 11336-11343.	3.4	99
3	Nuclear Export of Retinoid X Receptor α in Response to Interleukin-1β-mediated Cell Signaling. Journal of Biological Chemistry, 2006, 281, 15434-15440.	3.4	95
4	Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sciences, 2011, 89, 57-64.	4.3	92
5	Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 901-923.	3.3	84
6	Drug Disposition in Pathophysiological Conditions. Current Drug Metabolism, 2012, 13, 1327-1344.	1.2	70
7	Antiapoptotic Function of Cdk9 (TAK/P-TEFb) in U937 Promonocytic Cells. Journal of Virology, 2001, 75, 1220-1228.	3.4	48
8	Role of c-Jun N-terminal kinase (JNK) in regulating tumor necrosis factor-alpha (TNFALPHA.) mediated increase of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine hepatocytes. Journal of Toxicological Sciences, 2010, 35, 163-173.	1.5	38
9	Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics–small molecule drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 605-616.	3.3	35
10	Rosiglitazone attenuates suppression of RXRα-dependent gene expression in inflamed liver. Journal of Hepatology, 2007, 46, 115-123.	3.7	34
11	Differential Role of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein in Toll-Like Receptor 2-Mediated Regulation of Gene Expression of Hepatic Cytokines and Drug-Metabolizing Enzymes. Drug Metabolism and Disposition, 2011, 39, 874-881.	3.3	33
12	Regulation of Hepatic Drug-Metabolizing Enzyme Genes by Toll-Like Receptor 4 Signaling Is Independent of Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein. Drug Metabolism and Disposition, 2008, 36, 95-101.	3.3	32
13	Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Toll-like receptor 2 ligand, lipoteichoic acid. Archives of Biochemistry and Biophysics, 2009, 481, 123-130.	3.0	32
14	Role of Constitutive Androstane Receptor in Toll-Like Receptor-Mediated Regulation of Gene Expression of Hepatic Drug-Metabolizing Enzymes and Transporters. Drug Metabolism and Disposition, 2014, 42, 172-181.	3.3	31
15	Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice. Toxicology and Applied Pharmacology, 2013, 266, 430-438.	2.8	24
16	Neratinib in HER2-Positive Breast Cancer Patients. Annals of Pharmacotherapy, 2019, 53, 612-620.	1.9	22
17	Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 1109-1124.	3.3	20
18	Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt. Toxicology and Applied Pharmacology, 2020, 398, 115032.	2.8	19

Romi Ghose

#	Article	IF	CITATIONS
19	Role of c-Jun-N-Terminal Kinase in Pregnane X Receptor-Mediated Induction of Human Cytochrome P4503A4 In Vitro. Drug Metabolism and Disposition, 2018, 46, 397-404.	3.3	14
20	Transcriptomic profiling identifies novel mechanisms of transcriptional regulation of the cytochrome P450 (Cyp)3a11 gene. Scientific Reports, 2019, 9, 6663.	3.3	14
21	Phosphorylation of Xenopus transcription factor IIIA by an oocyte protein kinase CK2. Biochemical Journal, 2002, 362, 375.	3.7	10
22	Role of Adaptor Protein Toll-Like Interleukin Domain Containing Adaptor Inducing Interferon in Toll-Like Receptor 3- and 4-Mediated Regulation of Hepatic Drug Metabolizing Enzyme and Transporter Genes. Drug Metabolism and Disposition, 2015, 44, 61-67.	3.3	10
23	Impact of diet on irinotecan toxicity in mice. Chemico-Biological Interactions, 2018, 291, 87-94.	4.0	10
24	Phosphorylation of Xenopus transcription factor IIIA by an oocyte protein kinase CK2. Biochemical Journal, 2002, 362, 375-382.	3.7	9
25	Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Life Sciences, 2015, 139, 132-138.	4.3	9
26	In Vitro Approaches to Study Regulation of Hepatic Cytochrome P450 (CYP) 3A Expression by Paclitaxel and Rifampicin. Methods in Molecular Biology, 2016, 1395, 55-68.	0.9	9
27	Restricted Specificity of Xenopus TFIIIA for Transcription of Somatic 5S rRNA Genes. Molecular and Cellular Biology, 2004, 24, 2467-2477.	2.3	8
28	Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. Toxicology in Vitro, 2017, 41, 75-82.	2.4	7
29	Role of oxidative stress in the efficacy and toxicity of herbal supplements. Current Opinion in Toxicology, 2020, 20-21, 36-40.	5.0	7
30	Immunization and Drug Metabolizing Enzymes: Focus on Hepatic Cytochrome P450 3A. Expert Review of Vaccines, 2021, 20, 623-634.	4.4	6
31	Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice. Toxicology Research, 2022, 11, 184-194.	2.1	6
32	Impact of hepatic malignancy on CYP3A4 gene expression. Journal of Surgical Research, 2012, 178, 768-772.	1.6	5
33	Inhibition of RNA polymerase III transcription by a ribosome-associated kinase activity. Nucleic Acids Research, 1998, 26, 4758-4764.	14.5	4
34	Effects of inflammation on irinotecan pharmacokinetics and development of a best-fit PK model. Chemico-Biological Interactions, 2020, 316, 108933.	4.0	4
35	lrinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea. Food and Chemical Toxicology, 2022, 166, 113246.	3.6	3
36	Altered Drug Metabolism and Transport in Pathophysiological Conditions. , 2012, , .		2

#	Article	IF	CITATIONS
37	Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation. Chemico-Biological Interactions, 2022, 360, 109946.	4.0	2
38	Differential Regulation of Hepatic UDPâ€glucuronosyltransferase (UGT) 1A1 by Tollâ€like Receptors during Irinotecanâ€induced Steatosis. FASEB Journal, 2020, 34, 1-1.	0.5	1